Speak with a Defective Drug Specialist
Get answers to legal & medical questions
patient advocate


Latest News

Date posted: 1/21/2014

DrugRisk continues to follow developments with the popular blood thinner Pradaxa, and recent news suggests bleeding risks of the drug could be driving new studies from the FDA and increased legal action against the manufacturer, Boehringer Ingelheim.
DrugRisk learned this week that the federal Pradaxa multidistrict litigation court will hold its latest hearing on January 24th after the most recent figures indicated a 6% jump in the number of lawsuits filed for internal bleeding.
Court records for January show that 2,057 patients or families have already filed a Pradaxa lawsuit, up from 1,936 last month.
Judge David Herndon, who is overseeing the litigation, previously ordered that cases can proceed against Boehringer, despite efforts by the German drug maker to dismiss them.
Last week, DrugRisk reported that the FDA is planning a fresh review of patient data to measure whether Pradaxa has higher rates of internal bleeding and blood clots than traditional treatment warfarin. Interestingly, they are not including rivals Eliquis or Xaralto in the study.
Pradaxa was introduced in 2010 to help prevent blood clots and stroke in patients with atrial fibrillation. It was meant to be an easier alternative to warfarin, which required patients to get regular blood tests. However, doctors soon noticed there was no antidote to stop internal bleeding in emergencies like with warfarin.
As a result, thousands of patients have died or been hospitalized with emergency internal bleeding while taking Pradaxa. It has consistently ranked near the top of all drugs for number of adverse reports to the FDA and has been linked to 5 times the risk of death and 55% higher risks of blood clots than warfarin.
Recently, Judge Herndon fined Boehringer nearly $1 million for failing to turn over evidence about Pradaxa’s development and marketing to patients filing lawsuits.
The company has good reason to protect its product, however. Last year they earned over $1 billion and sold the drug in more than 70 countries.
If you or a loved one suffered internal bleeding after taking Pradaxa, it is important to speak with a lawyer today about your rights to file a lawsuit. You may be entitled to substantial compensation. However, time is limited.
Due to the specialized nature of these cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits. Contact us today for more information on Pradaxa, or to speak with a lawyer.